NICE TAs

28/04/2020

TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

28/04/2020

TA513: Obinutuzumab for untreated advanced follicular lymphoma

28/04/2020

TA568: Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)

28/04/2020

TA534: Dupilumab for treating moderate to severe atopic dermatitis

28/04/2020

TA521: Guselkumab for treating moderate to severe plaque psoriasis

28/04/2020

TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

28/04/2020

TA546: Padeliporfin for untreated localised prostate cancer

28/04/2020

TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

28/04/2020

TA565: Benralizumab for treating severe eosinophilic asthma

28/04/2020

TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs

28/04/2020

TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

28/04/2020

TA585: Ocrelizumab for treating primary progressive multiple sclerosis

28/04/2020

TA542: Cabozantinib for untreated advanced renal cell carcinoma

28/04/2020

TA523: Midostaurin for untreated acute myeloid leukaemia

28/04/2020

TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia

28/04/2020

TA623: Patiromer for treating hyperkalaemia

28/04/2020

TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia

23/04/2020

TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

23/04/2020

TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

23/04/2020

TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs